A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Latest Information Update: 06 Mar 2026
At a glance
- Drugs AZD-6234 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ARAY
- Sponsors AstraZeneca
Most Recent Events
- 03 Mar 2026 Planned End Date changed from 8 Jul 2026 to 27 May 2026.
- 03 Mar 2026 Planned primary completion date changed from 8 Jul 2026 to 27 May 2026.
- 03 Mar 2026 Status changed from recruiting to active, no longer recruiting.